Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn’s disease

Figure 2 Cumulative closure and recurrence rates after stem cell transplantation. All recurrences were detected in 3 years during the 5-year follow-up period after stem cell transplantation. The final cumulative closure rate (green line) excluding those who had recurrence (red line) was about 66.1% after stem cell transplantation regardless of the anti-tumor necrosis factor (TNF) therapy. The anti-TNF agents used in this study were infliximab (Remicade^®, Janssen Biotech, Inc., Horsham, PA, United States) and adalimumab (Humira^®, AbbVie, Inc., North Chicago, IL, United States).